


REMARKS

Claims 1-6 have been amended prior to examination, claims 7 and 8 have been cancelled without prejudice and claims 9 and 10 have been added. These amendments were made in order to make corrections to the claim sentence structure for grammatical purposes, to eliminate the term "optionally" and to eliminate brackets used in chemical names, and not for purposes of patentability under 35 USC 101,102,103 or 112. It is respectfully submitted that no estoppel is created by this amendment.

Respectfully submitted,



William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Attorney Docket No. O/98411 US
Akzo Nobel Patent Department
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850
Tel: (301) 948-7400
Fax: (301) 948-9751

WMB:lcf
41TIMMERS PRE-AMENDMENT

09830222 061101

1. (Amended) [Serine] A serine protease inhibitor having the formula (I),



in which

J is $H, R^1, R^1-O-C(O)-, R^1-C(O)-, R^1-SO_2-, R^3OOC-(CHR^2)_p-,$
 $(R^{2a}, R^{2b})N-CO-(CHR^2)_p-$ or $Het-CO-(CHR^2)_p-$;

D is an amino-acid of the formula $-NH-CHR^1-C(O)-,$
 $-NR^4-CH[[]((CH_2)_qC(O)OR^1[[]])]-C(O)-,$
 $-NR^4-CH[[]((CH_2)_qC(O)N(R^{2a}, R^{2b})[[]])]-C(O)-,$
 $-NR^4-CH[[]((CH_2)_qC(O)Het[[]])]-C(O)-,$
 D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq or D-3
 Piq;

E is $-NR^2-CH_2-$ or the fragment

, [optionally] which is

unsubstituted or substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R^1 is selected from (1-12C)alkyl,

(2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and
 (3-12C)cycloalkyl(1-6C)alkylene, which groups [may
 optionally be] are unsubstituted or substituted with
 (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF_3 or
 halogen, and from

(6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and

(14-20C) (bisary)alkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl,
 (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF₃ or halogen;
 R², R^{2a} and R^{2b} are each independently selected from
 H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl,
 (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene,
 which [can each be optionally] are unsubstituted or substituted with
 (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen, and
 from (6-14C)aryl and (7-15C)aralkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with
 (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen;
 R³ is [as defined for] the same as R² or is
 Het-(1-6C)alkyl;
 R⁴ is H or (1-3C)alkyl;
 X and Y are CH or N, with the proviso that they are not both N;
 Het is a 4-, 5- or 6-membered heterocycle containing
 one or more heteroatoms selected from O, N and S;
 m is 1 or 2;
 p is 1, 2 or 3;
 q is 1, 2 or 3;
 t is 2, 3 or 4;
 [or a prodrug;]
 [and/or] or a pharmaceutically acceptable addition salt
 [and/or] or solvate
 thereof.

093027 06401
 10790 2202860


2. (Amended) [Serine] The serine protease inhibitor according to claim 1, wherein m is 2; X is CH and Y is CH.

3. (Amended) The serine protease inhibitor according to claim 2, wherein

J is H, $R^1 R^1-SO_2-$, $R^3OOC-(CHR^2)_p-$,
 $(R^{2a}, R^{2b})N-CO-(CHR^2)_p-$ or Het-CO(CHR²)_p;

D is an amino-acid of the formula $-NH-CHR^1-C(O)-$,
 $-NR^4-CH[[]]((CH_2)_qC(O)OR^1[[]])C(O)-$,
 $-NR^4-CH[[]]((CH_2)_qC(O)N(R^{2a}, R^{2b})[[]])C(O)-$,

E is $-N(3-6C)cycloalkyl-CH_2-$ or the fragment



, [optionally] which is unsubstituted or
substituted with (1-6C)alkyl or
(1-6C)alkoxy;

R¹ is selected from (1-12C)alkyl, (3-12C)cycloalkyl and
(3-12C)cycloalkyl(1-6C)alkylene, which groups [may
optionally be] are unsubstituted or substituted with
(3-12C)cycloalkyl, (1-6C)alkoxy or oxo, and from
(6-14C)aryl, (7-15C)aralkyl and (14-
20C)(bisaryl)alkyl, [whereby]
wherein the aryl groups [may optionally be] are
unsubstituted or substituted with (1-6C)alkyl,
(3-12C)cycloalkyl,
(1-6C)alkoxy, OH, CF₃ or halogen;

R² is H;

R^{2a} and R^{2b} are each independently selected from H,
 (1-8C)alkyl, (3-8C)cycloalkyl and
 (3-6C)cycloalkyl(1-4C)alkylene, which [can each be
 optionally] are unsubstituted or substituted with
 (3-6C)cycloalkyl or (1-6C)alkoxy and from
 (6-14C)aryl and (7-15C)aralkyl, [whereby] wherein
 the aryl groups [may optionally be] are
unsubstituted or substituted with (1-6C)alkyl,
 (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen;
 R³ is selected from H, (1-8C)alkyl, (3-8C)cycloalkyl
 and (3-6C)cycloalkyl(1-4C)alkylene, which [can each
 be optionally] are unsubstituted or substituted with
 (3-6C)cycloalkyl or (1-6C)alkoxy, and from
 (7-15C)aralkyl, [whereby] wherein the aryl groups
 [may optionally be] are unsubstituted or substituted
 with (1-6C)alkyl,
 (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen and
 from Het-(1-6C)alkyl;
 p is 1;
 q is 2;
 t is 3 or 4.

4. (Amended) [Serine] The serine protease inhibitor
 according to claim 3, wherein

D is an amino-acid of the formula -NH-CHR¹-C(O)- or
 glutamyl[[] or an (1-6C)alkylester thereof[[]];
 R¹ is selected from (3-12C)cycloalkyl and
 (3-12C)cycloalkyl(1-6C)alkylene, which groups [may
 optionally be] are unsubstituted or substituted with
 (3-12C)cycloalkyl
 or (1-6C)alkoxy, and from (6-14C)aryl, (7-
 15C)aralkyl and (14-20C)(bisary)alkyl, [whereby]

09030227 061101

wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy or halogen; and


R³ is selected from (1-8C)alkyl and (3-8C)cycloalkyl, which [can each be optionally] are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen and from Het-(1-6C)alkyl.

5. (Amended) [Serine] The serine protease inhibitor according to claim 4, wherein

J is -CH₂COO(1-6C)alkyl, (3-8C)cycloalkyl, -SO₂-10-camphor, -CH₂CONHphenyl or -CH₂CONH(3-8C)cycloalkyl;

D is D-cyclohexylalaninyl, D-phenylalaninyl, D-diphenylalaninyl or glutamyl, [[or an (1-6C)alkylester thereof]]; and

E is the fragment



, wherein t is 3 or 4.

6. (Amended) A pharmaceutical composition comprising the serine protease inhibitor of [any one of claims 1 to 5] claim 1 and at least one pharmaceutically suitable [auxiliaries] auxiliary.

09830227 064101